Successful employment of brentuximab vedotin in a patient undergoing hemodialysis: the first real life experience

Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Laura Nanni, Cinzia Pellegrini, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSIONThe majority of real-world RRMM patients were ineligible for hallmark RCTs. Eligibility rates varied across RCTs, underlining the flawed nature of cross-study comparisons without RCT validation. OS was significantly affected by inability to meet criteria highlighting limited generalizability of RCT results. Greater efforts should be made to broaden eligibility criteria to reflect real-world clinical characteristics to narrow the gap between RCT efficacy and observed effectiveness in real-world MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThese results support the claim that MRD status can be used as a surrogate for PFS in NDMM.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joseph MikhaelAbstractThe advent of new, more effective, and less toxic therapies has revolutionized the management of multiple myeloma in the past decade. Despite the availability of new treatments, the majority of patients with multiple myeloma will become refractory to the therapies that currently comprise the hematologic standard of care for the malignancy: proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Moreover, in recent years, a new subset of patients refractory to all 3 of these agen...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOutpatient ASCT is a safe and feasible treatment strategy with low TRM. Overall resource utilization are significantly lower than inpatient auto-transplantation: however, this requires a multidisciplinary approach with close follow up
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): James Yeung, Sebastiaan van Hal, P. Joy Ho
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Maria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, Ajay K. Nooka, Jane A. Estell, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Eva Medvedova, Katja Weisel, Christopher Chiu, Jordan M. Schecter, Himal Amin, Xiang Qin, Jon Ukropec, Rachel Kobos, Andrew SpencerAbstractBackgroundIn the phase 3 CASTOR study in relapsed or refractory multiple myeloma (RRMM), daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are di...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Anastasios Kyriazoglou, Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Despina Fotiou, Efstathios Kastritis, Meletios A. Dimopoulos, Maria GavriatopoulouAbstractMultiple myeloma (MM) is an incurable plasma cell dyscrasia with numerous treatment options currently available; however, drug resistance is usually inevitable. Thus, there is a constant need for novel treatment approaches. The Hippo pathway has emerged as an important mediator of oncogenesis in solid tumors. More recently, its key role in regulating apoptosi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hira Mian, Mark Fiala, Tanya M. WildesAbstractIntroductionOne of the most common orally administered anti-myeloma agent, lenalidomide, has significantly improved outcomes in multiple myeloma, including in older patients. However, despite its utilization and cost, the rates and factors related to adherence to lenalidomide in older adults with newly-diagnosed multiple myeloma remain unknown.Patients and MethodsData from adults with newly-diagnosed multiple myeloma over age 65 being treated with lenalidomide therapy betwe...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study evaluates a cohort of 30 patients with newly diagnosed NSMM seen at the Mayo Clinic, Rochester between 2008 to 2018 and treated with novel agent induction therapies. Survival outcomes were estimated using the Kaplan-Meier method and compared using log rank test.Results and conclusions: These patients with NSMM appear to have a large disease burden at diagnosis with a median bone marrow plasma cell percentage of 70% and more than half of all patients having ISS Stage III disease. There was a higher preponderance for t(11;14) primary cytogenetic abnormality in this NSMM cohort accounting for more than 50% of the c...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe prevalence of PNH clones in MPN is similar to that described in myelodysplastic syndromes. Whether PNH clones influence MPN phenotype and complications should be studied prospectively in larger patient cohorts and over long-term follow-up.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Dialysis | Employment | Hemodialysis | Leukemia | Lymphoma | Myeloma